Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (2)

2016

  1. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

    British Journal of Cancer, Vol. 114, Núm. 4, pp. 372-380

2015

  1. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 7, pp. 859-870